In the VELVET clinical trial of vinorelbine in combination with trastuzumab and pertuzumab for the first-line treatment of HER2-positive breast cancer, treatments were dosed sequentially (Cohort 1) and found to be reasonably well tolerated [18]; similar results were obtained when trastuzumab and pertuzumab were co-infused, followed by vinorelbine (Cohort 2) [19]. Here, ERBB2 is linked to breast cancer.